BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23524907)

  • 1. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium.
    Fadare O; Gwin K; Desouki MM; Crispens MA; Jones HW; Khabele D; Liang SX; Zheng W; Mohammed K; Hecht JL; Parkash V
    Mod Pathol; 2013 Aug; 26(8):1101-10. PubMed ID: 23524907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
    BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.
    Allo G; Bernardini MQ; Wu RC; Shih IeM; Kalloger S; Pollett A; Gilks CB; Clarke BA
    Mod Pathol; 2014 Feb; 27(2):255-61. PubMed ID: 23887303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma.
    Zhang ZM; Xiao S; Sun GY; Liu YP; Zhang FH; Yang HF; Li J; Qiu HB; Liu Y; Zhang C; Kang S; Shan BE
    Int J Gynecol Cancer; 2014 Mar; 24(3):534-40. PubMed ID: 24557437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the Loss of ARID1A (BAF-250a) Expression in Endometrial Clear Cell Carcinomas Have Any Clinicopathologic Significance? A Pilot Assessment.
    Fadare O; Renshaw IL; Liang SX
    J Cancer; 2012; 3():129-36. PubMed ID: 22408686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts.
    Wiegand KC; Sy K; Kalloger SE; Li-Chang H; Woods R; Kumar A; Streutker CJ; Hafezi-Bakhtiari S; Zhou C; Lim HJ; Huntsman DG; Clarke B; Schaeffer DF
    Hum Pathol; 2014 Jun; 45(6):1258-68. PubMed ID: 24767857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
    PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.
    Xiao W; Awadallah A; Xin W
    Int J Clin Exp Pathol; 2012; 5(7):642-50. PubMed ID: 22977660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
    Lowery WJ; Schildkraut JM; Akushevich L; Bentley R; Marks JR; Huntsman D; Berchuck A
    Int J Gynecol Cancer; 2012 Jan; 22(1):9-14. PubMed ID: 22193641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
    Samartzis EP; Samartzis N; Noske A; Fedier A; Caduff R; Dedes KJ; Fink D; Imesch P
    Mod Pathol; 2012 Jun; 25(6):885-92. PubMed ID: 22301703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer.
    Rahman M; Nakayama K; Rahman MT; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Miyazaki K
    Hum Pathol; 2013 Jan; 44(1):103-9. PubMed ID: 22939958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
    Katagiri A; Nakayama K; Rahman MT; Rahman M; Katagiri H; Nakayama N; Ishikawa M; Ishibashi T; Iida K; Kobayashi H; Otsuki Y; Nakayama S; Miyazaki K
    Mod Pathol; 2012 Feb; 25(2):282-8. PubMed ID: 22101352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
    Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance.
    Fadare O; Liang SX; Crispens MA; Jones HW; Khabele D; Gwin K; Zheng W; Mohammed K; Parkash V; Hecht JL; Desouki MM
    Hum Pathol; 2013 Aug; 44(8):1508-15. PubMed ID: 23465280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
    Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
    Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.
    Choi JY; Han HH; Kim YT; Lee JH; Kim BG; Kang S; Cho NH
    Yonsei Med J; 2017 Jan; 58(1):59-66. PubMed ID: 27873496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.
    Wiegand KC; Lee AF; Al-Agha OM; Chow C; Kalloger SE; Scott DW; Steidl C; Wiseman SM; Gascoyne RD; Gilks B; Huntsman DG
    J Pathol; 2011 Jul; 224(3):328-33. PubMed ID: 21590771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
    Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P; MacKay HJ; Powell ME; Bosse T; Creutzberg CL; Kitchener HC
    Gynecol Oncol; 2017 Aug; 146(2):327-333. PubMed ID: 28511869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic Significance of HNF-1β, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.
    Ye S; Yang J; You Y; Cao D; Huang H; Wu M; Chen J; Lang J; Shen K
    Medicine (Baltimore); 2016 Mar; 95(9):e3003. PubMed ID: 26945423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.